stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) EPS (diluted)
Fortrea Holdings Inc.'s EPS (diluted) for fiscal 2025 was −$10.81, compared with −$3.67 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.73. Over the past ten years it has ranged from −$10.81 (fiscal 2025) to $2.10 (fiscal 2022) — the current reading is the lowest in ten years. EPS (diluted) has fallen for 3 consecutive fiscal years. Fortrea Holdings Inc. ranks 167th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$10.81 | — |
| FY2024 | −$3.67 | — |
| FY2023 | −$0.29 | — |
| FY2022 | $2.10 | 90.00% |
| FY2021 | $1.10 | — |
| FY2020 | −$4.05 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.01 | — |
| Jun 2026 | −$0.14 | — |
| Mar 2026 | −$0.25 | — |
| Dec 2025 | −$0.35 | — |
| 13 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | $3.02 |
| FTRE Fortrea Holdings Inc. | −$0.73 |
| VIR Vir Biotechnology, Inc. compare | −$1.26 |
| SRPT Sarepta Therapeutics, Inc. compare | −$1.37 |
| ZYME Zymeworks Inc. compare | −$2.02 |
| IMNM Immunome, Inc. compare | −$2.53 |
| REPL Replimune Group, Inc. compare | −$2.79 |
| BHVN Biohaven Ltd. compare | −$3.86 |
| TRAX First Tracks Biotherapeutics, Inc. compare | −$5.17 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item